Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take-home message of the LATITUDE study at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Advertisement